Seventh Straight Decline: Nifty Falls Harder Than the Morning Expected

Expected vs Actual Performance Analysis:

Our morning brief anticipated a "soft/flat start" with GIFT Nifty around 24,900 levels, but markets delivered a sharper decline than projected. The pharma tariff impact materialized more severely than expected, with the sector declining 2.2% versus our cautious positioning.

Key Validation:

Morning Prediction: Nifty soft start around 24,900
Actual Outcome: Nifty opened weak and closed at 24,654.70 [Official]
Deviation: -245 points worse than morning expectations Subscriber Feedback Synthesis: Market participants expressed concern over the cascading effect of Trump's pharma tariffs, with several noting the broader implications for India's $10.5 billion pharmaceutical export market to the US. Our views on the same remain as follows:

On Oct 1, 2025, the United States plans to impose a 100% tariff on imports of branded or patented pharmaceutical products,with exemptions forcompanies thathavealready broken ground on new US manufacturing. Generics are not targeted. For NIFTY Pharma (India), direct tariff risk is concentrated inspecialty/brandedproductssoldintotheUSandinfirmswithoutflexibleUSmanufacturingoptions. API-focused firms face minimal direct risk; indirect effects (sourcing, partner behavior) remain watch items.

2Key Movements in Indian Equity Markets

VALIDATED CLOSES (26-Sep-2025):

Nifty 50: 24,654.70 (-236.15 pts, -0.95%) [Official]
Sensex: 80,426.46 (-733.22 pts, -0.90%) [Official]
Bank Nifty: 54,389.35 (-586.85 pts, -1.07%) [Official]

Sector Performance Analysis:

All major sectoral indices closed in negative territory, with broad-based selling pressure. IT sector led losses at -2.3%, followed by Pharma at -2.2%, reflecting direct impact from Trump's policy announcements. Banking sector declined 1.0% amid concerns over sustained FII outflows and rupee weakness.

Under-reported Pattern: Despite the seventh consecutive decline, Nifty's one-year performance shows onlya 5.5%drop fromits September2024 peakof 26,277, indicating relative market resilience compared to individual stock performances where 485 of top mid and small-cap stocks have declined over 20%.

Under-reported micro pattern: Breadth deterioration was broad but intensity clustered in high- US-exposure cohorts (large-cap IT + export-oriented pharma) while some domestic cyclicals held relatively steadier on a beta-adjusted basis — a reminder that external-shock beta > domestic- demand beta on such days. (We’ll quantify with AD ratios & beta-bucketing in tomorrow’s follow-up.)

Technical Levels Analysis:

Nifty Support: 24,600-24,650 (tested and held intraday)
Nifty Resistance: 24,850-24,900 (previous support turned resistance)
Bank Nifty Critical Level: 54,000 (key psychological support ahead.

3Economic Data & FX

INR/USD Movement:

FBIL Reference: 88.67 (25-Sep-2025, latest available)
Spot/Futures: Trading around 88.72 levels [Provisional]
Trend: INR continues near record-weak zones, pressured by sustained FII outflows

FII/DII Activity:

FII Cash: -Rs 4,995.42 crore (25-Sep, contributing to September outflows of Rs 13,450 crore) [Provisional]
DII Activity: Rs 17,064.63 crore (26-Sep) [Provisional]

4Market Sentiment Indicators

Put-Call Ratio Analysis: Nifty PCR hovering around oversold territory, suggesting potential for technical bounce despite fundamental headwinds.

India VIX: Elevated levels reflecting heightened uncertainty around US trade policies and their sectoral implications.

Breadth Analysis: Market breadth severely negative with only 8 Nifty 50 stocks advancing versus 42 declining, indicating broad-based pessimism. Breadth negative across large/mid/small; wraps cite broad-based decline with 15/16 sectors lower intraday

5Data-Driven Trade Ideas (education only)

Top 5 Stocks to Watch:

L&T - Top Nifty gainer (+1.5%), benefiting from infrastructure focus[4]
Tata Motors - Recovered 2% after JLR cyber-attack resolution
Sun Pharma - Hit 52-week low, potential value opportunity post-tariff clarity
Maruti Suzuki - Achieved 52-week high, showing auto sector resilience
ITC - Defensive play holding ground amid broader market decline Options Strategy: Given elevated volatility, consider iron condor strategies on Bank Nifty with 54,000-55,000 range, capitalizing on time decay while managing directional risk.
Bear Call Spread on Nifty 25,000/25,200 (30-Sep) to express resistance band; limited risk.

[Provisional OI].

Protective Put near 24,600–24,700 (30-Sep/07-Oct roll) given VIX uptick yet subdued absolute level. [Provisional OI].
Pharma dispersion: Prefer pair trades (US-exposure & pipeline mix) over blanket sector shorts amid tariff-policy unknowns. Macro & Global: Tariff headlines dominated; IT sentiment also influenced by Accenture revenue outlook in prior sessions.

6Educational Segment - Term of the Day

"Tariff Pass-Through" - The mechanism by which import duties translate into domestic price changes. In pharma, companies face a strategic choice: absorb margin compression or accelerate US manufacturing investments to bypass tariffs entirely.

7Forward Outlook & Subscriber Engagement

Monday Watch Levels:

Nifty: Break below 24,600 could trigger 24,450-24,500 test.
Sensex: 80,000 psychological support critical.
Bank Nifty: 54,000 breakdown opens 53,600 target. Upcoming Catalysts: US PCE inflation data outcome and any pharmaceutical sector guidance from industry bodies will drive Monday's sentiment.

Compliance & Disclaimers:

This newsletter is for informational and educational purposes only and does not constitute investment advice. 'Provisional' data is subject to revision by sources and will be reconciled next trading day. Market investments carry inherent risks, and past performance does not guarantee future results. Readers should conduct independent research and consult qualified financial advisors before making investment decisions.